Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–87 of 87 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Early Parkinson's Disease Clear all

Conditions: Parkinson Disease
Interventions: HB-adMSCs, Placebo; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Parkinson Disease
Interventions: Placebo, PF-06649751; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 20
States / cities: Phoenix, Arizona • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: Parkinsons Disease (PD)
Interventions: Gamma- glutamylcysteine; Drug
Lead sponsor: Pravat Mandal; Other
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Early Stage Parkinson's Disease
Interventions: Pardoprunox, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 20 more

Conditions: Parkinson's Disease (PD)
Interventions: NUSHU shoe; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson Disease
Interventions: sumanirole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more

Conditions: Parkinson's Disease, Healthy
Interventions: BIIB054, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more

Conditions: REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions: Carvedilol; Drug
Lead sponsor: Michele Tagliati, MD; Other
Eligibility: 50 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Early-Stage Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 31 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Parkinson Disease
Interventions: BHV-8000 10mg, BHV-8000 20 mg, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Irvine, California • Los Angeles, California + 21 more

Conditions: Parkinson Disease, Parkinsonian Syndrome
Interventions: levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging; Drug · Procedure
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 30 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 13
States / cities: Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more

Conditions: Parkinson Disease
Interventions: RO7486967, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more

Conditions: Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions: Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator; Behavioral · Device · Biological + 1 more
Lead sponsor: Noah Tech, Corp.; Industry
Eligibility: 55 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palisades Park, New Jersey

Conditions: Parkinson Disease
Interventions: pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 32
States / cities: Brimingham, Alabama • Scottsdale, Arizona • La Jolla, California + 28 more

Conditions: Parkinson Disease
Interventions: Smartphone microphone sensor, Smartphone accelerometer sensor; Device
Lead sponsor: Goalspal LLC; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pleasanton, California

Search by objective public record fields.

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

SLV308 for Treatment of Patients With Early Parkinson's Disease

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

A Study to Analyze Symptoms Prevalent in Early PD (Dysphonia, Tremor)